Queen's University at Kingston

Huntsman Cancer Institute joins myeloMATCH, a National Cancer Institute-sponsored program matching AML/MDS patients with trials based on genetic signatures, aiming to advance precision medicine. Patients undergo bone marrow biopsy for diagnosis and are assigned trials based on disease type and response to therapy, using groundbreaking technology to detect measurable residual disease (MRD).

Huntsman Cancer Institute joins an innovative clinical trials program, myeloMATCH, to match AML and MDS patients with trials based on their genetic signature, aiming to improve precision medicine and personalized cancer care.

NIH's NCI launches myeloMATCH trial to test precision medicine treatments for AML and MDS, aiming to accelerate discovery of tailored treatments. Participants undergo rapid genetic testing to match with appropriate substudy treatments, with the goal of enrolling several thousand within the first few years.

NHKI researchers shared expertise at international healthcare conferences, including a platform trial meeting in Dublin and the ESICM Congress in Barcelona, highlighting their commitment to global health research equity.

Four leading cancer research organizations in the U.S. and Canada open patient enrollment for myeloMATCH, a precision medicine clinical trial portfolio for AML and MDS. The trials, led by the NCI's NCTN, aim to accelerate precision medicine in myeloid malignancies and develop new therapies. myeloMATCH offers advanced biomarker testing at no cost, with results returned within three days, and is structured into four tiers based on the patient's treatment stage.

NIH's NCI launches myeloMATCH trial to test precision medicine treatments for AML and MDS, aiming to accelerate tailored treatment discovery through rapid genetic testing and targeted drug combinations.

NIH's myeloMATCH trial tests new treatment combinations for AML and MDS based on genetic changes, aiming to accelerate tailored treatments. Participants undergo rapid genetic testing to match with appropriate substudies or standard treatment, with further testing as disease reduces. The trial aims to enroll thousands and refine assays to understand treatment resistance.

Four leading cancer research organizations in the U.S. and Canada open patient enrollment for myeloMATCH, a precision medicine clinical trial portfolio for adults with AML or MDS. The trials, designed by the Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG Cancer Research Network, aim to accelerate precision medicine in myeloid malignancies and develop new therapies. Three treatment trials are now open, with more in development, and researchers hope to enroll 5,000 or more patients. myeloMATCH offers advanced biomarker testing at no cost, with results returned within three days, and structured into four tiers based on the patient's treatment journey.

The NIH's myeloMATCH initiative, a portfolio of biomarker-driven precision medicine clinical trials, aims to test new treatments for myeloid cancers, enrolling patients from diagnosis through treatment stages. The trials, organized into four tiers addressing different stages of cancer treatment, use rapid genetic testing and next-generation sequencing to match patients with appropriate treatments, aiming to reduce tumor burden and target residual disease effectively.

myeloMATCH uses genomics to enroll leukemia patients in targeted trials, aiming to accelerate effective treatment identification.